Pascal Deschatelets - May 8, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
May 8, 2024
Transactions value $
-$3,001,759
Form type
4
Date filed
5/9/2024, 05:15 PM
Previous filing
Apr 9, 2024
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $340K +78.9K +7.07% $4.31* 1.19M May 8, 2024 Direct F1
transaction APLS Common Stock Sale -$2.37M -56.3K -4.71% $42.15 1.14M May 8, 2024 Direct F1, F2
transaction APLS Common Stock Sale -$963K -22.5K -1.97% $42.85 1.12M May 8, 2024 Direct F1, F3
transaction APLS Common Stock Sale -$4.4K -100 -0.01% $44.03 1.12M May 8, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -78.9K -42.08% $0.00 109K May 8, 2024 Common Stock 78.9K $4.31 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
F2 This transaction was executed in multiple trades at prices ranging from $41.575 - $42.570. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $42.575 - $43.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This stock option was granted on 08/21/2017 and is fully vested.